Su Jin Kim
Kwandong University
OphthalmologyCompound heterozygosityInternal medicineEndocrinologySurgeryGlycosaminoglycanPediatricsImmunologyHunter syndromeOsteogenesis imperfectaShort statureIduronate-2-sulfatasePeritoneal dialysisDiseaseEnzyme replacement therapyHypophysectomyPopulationMucopolysaccharidosis type IIGrowth hormoneIn patientAnesthesiaMutationGeneticsMedicineBiologyGastroenterology
Publications 58
#1Ji Hyun KimH-Index: 1
#2Eun Young ParkH-Index: 6
Last. Hye-Seon JeonH-Index: 12
view all 7 authors...
#1Sang Min LeeH-Index: 24
#2Su Hwan ParkH-Index: 1
Last. Su Jin KimH-Index: 14
view all 4 authors...
Last. Miri Kwon
view all 6 authors...
#1Aram YangH-Index: 8
#2Dong-Kyu Jin (SMC: Samsung Medical Center)H-Index: 21
Last. Sung Yoon Cho (SMC: Samsung Medical Center)H-Index: 14
view all 7 authors...
1 CitationsSource
#1Hyung Suk Jin (Green Cross International)H-Index: 1
#2Ho Young SongH-Index: 1
Last. Su Jin KimH-Index: 14
view all 7 authors...
5 CitationsSource
#1Jong In Jeong (KMU: Keimyung University)H-Index: 2
#2Jung Joo LeeH-Index: 5
Last. Hyo Yeol KimH-Index: 20
view all 9 authors...
#1Ah-Ra Ko (Samsung)H-Index: 11
#2Dong-Kyu Jin (SMC: Samsung Medical Center)H-Index: 21
Last. Young Bae Sohn (Ajou University)H-Index: 15
view all 11 authors...
Mucolipidoses II and III (ML II and ML III) are lysosomal disorders in which the mannose 6-phosphate recognition marker is absent from lysosomal hydrolases and other glycoproteins due to mutations in GNPTAB, which encodes two of three subunits of the heterohexameric enzyme, N-acetylglucosamine-1-phosphotransferase. Both disorders are caused by the same gene, but ML II represents the more severe phenotype. Bone manifestations of ML II include hip dysplasia, scoliosis, rickets and osteogenesis imp...
8 CitationsSource
#1Sung Yoon Cho (SMC: Samsung Medical Center)H-Index: 14
#2Jeehun Lee (SMC: Samsung Medical Center)H-Index: 13
Last. Dong-Kyu Jin (SMC: Samsung Medical Center)H-Index: 21
view all 8 authors...
Background Mucopolysaccharidosis type II (MPS II, Hunter syndrome), is caused by a deficiency of iduronate-2-sulfatase (IDS). Despite the therapeutic effect of intravenous enzyme replacement therapy (ERT), the central nervous system (CNS) defects persist because the enzyme cannot cross the blood-brain barrier (BBB). There have been several trials of direct infusion to the cerebrospinal space showing promising results; however, this approach may have limitations in clinical situations such as CNS...
13 CitationsSource